Sponsored Links 
Warner Chilcott Meets in Q1
Print
ShareWarner Chilcott Ltd.'s (WCRX) announced first-quarter EPS, excluding items, of 39 cents, which matched the consensus.
Revenues expanded 7% to $246 million, primarily due to the growth of Doryx, Loestrin 24 FE and Estrace Cream.
Warner Chillcott indicated that it continues to expect fiscal 2009 revenues to range between $1.015 billion and $1.025 billion.
The developer of woman healthcare products also affirmed full-year earnings guidance of $1.55 to $1.60 per share, excluding items, which is in-line with the $1.59 consensus derived from 12 analysts.
WCRX, Zacks #3 Rank ("Hold") stock, is about breakeven today with volume of approximately 616,000, which is lower than the average daily volume of about 1.02 million.
Read the full analyst report on WCRX
Loading Stories...
0.00 %
6.51